hsa-miR-206 |
LC |
0.02369 |
0.0313 |
Cell proliferation suppression, apoptosis |
Low |
[35, 36] |
hsa-miR-637 |
LC and HCC |
0.01019 and 0.006758 |
0.0156 and < 0.0001 |
LIF gene inhibition, induced STAT3 phosphorylation |
Low |
[33] |
hsa-miR-15b |
HCC |
0.03091 |
0.0010 |
Apoptosis, proliferation, survival and angiogenesis |
Low |
[37, 38] |
hsa-miR-125b |
HCC |
0.01632 |
0.0010 |
Cell invasion, tumour metastasis, VEGF regulation |
Low |
[37, 42] |
hsa-miR-423-3p |
HCC |
0.02558 |
0.0010 |
Cell proliferation, cell cycle |
Low |
[46, 48] |
hsa-miR-424 |
HCC |
0.004519 |
0.0313 |
Angiogenesis regulation and cell invasion |
Low |
[51, 53] |
hsa-miR-494 |
HCC |
0.006319 |
< 0.0001 |
Cell cycle, sorafenib resistance, PTEN regulation |
Low |
[59] |
hsa-miR-497 |
HCC |
0.04621 |
< 0.0001 |
Invasion, proliferation, cell growth and apoptosis |
Low |
[63–66] |
hsa-miR-612 |
HCC |
0.00605 |
0.0078 |
Metastasis suppressor |
Low |
[69] |
hsa-miR-1255b |
HCC |
0.00568 |
0.0156 |
No functional study in the literature |
Low |
– |